New retinoblastoma tumor formation in children initially treated with systemic carboplatin

Ophthalmology. 2003 Oct;110(10):1989-94; discussion 1994-5. doi: 10.1016/S0161-6420(03)00669-9.

Abstract

Purpose: To determine the frequency and timing of new intraocular tumor formation in children with hereditary retinoblastoma initially treated with systemic carboplatin.

Design: Retrospective, noncomparative case series.

Participants: This study included 34 children (57 eyes) with hereditary bilateral retinoblastoma initially treated with systemic carboplatin at the Robert M. Ellsworth Ophthalmic Oncology Center at NewYork-Presbyterian Hospital from 1994 through 2000.

Main outcome measures: New tumor formation after initial treatment with systemic carboplatin.

Results: There were a total of 165 tumors in 57 eyes. There were 63 new tumors in 27 eyes (47%) after administration of systemic carboplatin, for a mean of 1.1 new tumors per eye. The mean patient age at time of new tumor presentation was 9 months, with 57% of new tumors developing within 4 months of carboplatin treatment. Kaplan-Meier analysis showed that children who were treated when younger than 6 months of age were more likely to have new tumors (60%) compared with those treated after 6 months of age (31%; P = 0.0182).

Conclusions: New intraocular tumors continue to develop after systemic carboplatin; most new tumors appeared within 4 months of treatment.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Carboplatin / therapeutic use*
  • Child, Preschool
  • Female
  • Humans
  • Infant
  • Infant, Newborn
  • Male
  • Neoplasms, Second Primary / etiology*
  • Retinal Neoplasms / drug therapy
  • Retinal Neoplasms / etiology*
  • Retinoblastoma / drug therapy
  • Retinoblastoma / etiology*
  • Retrospective Studies
  • Risk Factors
  • Time Factors

Substances

  • Antineoplastic Agents
  • Carboplatin